ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at http://www.entremed.com/. (LOGO: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO) About EntreMed EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com/ and in various filings with the Securities and Exchange Commission. Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643 http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO http://photoarchive.ap.org/ DATASOURCE: EntreMed, Inc. CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations, of EntreMed, Inc., +1-240-864-2643 Web Site: http://www.entremed.com/

Copyright